This business information is not released now.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.

ReqMed Company, Ltd.
Pharmaceutical/Drug Discovery

last update:2013/8/19

Delegates :
Dr. Tadashi Matsumoto

Incorporated :
May   12 , 1998

Paid in Capital :
742 Million yen  

Employees :
11 人

Address :
Mitsui-Life Bldg. 1-7-23 Morino, Machida-City TOKYO

+81-42-732-2207 / +81-42-732-2208


Attachment :

Mission/Background :
ReqMed Company is a privately-held biopharma company, headquartered in Tokyo, Japan. The company name “ReqMed” is derived from our corporate mission, to provide "Required Medicine for all who request it". Since ReqMed was established in May 1998, ReqMed has been dedicated to bio and pharmaceutical industry as BioBiz Navigator. ReqMed is engaged in drug development and business consulting.

Technology & Business
ReqMed is focusing on the therapeutic areas with unmet medical needs, and we have our clinical-stage pipelines for Homocystinuria, Tropical Spastic Paraparesis (TSP), Osteoarthritis, and CNS diseases, such as ADHD, Schizophrenia and Parkinson's disease. Taking the collaboration with academia and our partner companies, and grants by the government and patient groups, ReqMed aims to conduct efficient and cost-effective development.
Meanwhile, as our business consulting services, ReqMed supports a variety of clients worldwide, such as pharmaceuticals, biotechs, diagnostics, medical device companies, CROs and CMOs in their business development, licensing and partnering activities.

Products & Service
Products & Service Name
Sodium Pentosan Polysulfate
Osteoarthritis (OA), Tropical Spastic Paraparesis (TSP) / HTLV-1 associated myelopathy (HAM)
Finding development and marketing partner
ADHD, Cognitive Impairment Associated with Schizophrenia, Dyskinesia in Parkinson's disease
Finding development and marketing partner
NDA filed
Homocystinuria, Pharmaceutical Development Support program
Approved in Japan by the end of 4Q in 2013

- NDA for Betaine was filed in Jpana at the end of March in 2013.
- A POC study of Eltoprazine for Cognitive Impairment in Schizophrenia as the TUNRS program supported by US-NIH was completed.
Hot news
At Alliance Promotion, we would like to introduce recent significant progress in Pentosan research and current situation of Pentosan program for the treatment of Tropical Spastic Paraparesis (TSP) / HTLV-1 associated myelopathy (HAM). In addition, we will introduce Betain, for which we filed a new drug application with the PMDA in March, and our other therapeutic programs.

Alliance strategy
- Drug development projects: We are seeking a co-development and marketing partner of Eltoprazine and Pentosan in Japan, Korea (for eltoprazine), China and Taiwan.
- Business consulting: We introduce a variety of clients' partnering opportunities, including licensing programs, drug discovery platforms, CMO services and preclinical CRO services. We also support our clients in their business development and licensing activities based on our expertise and global network in the pharma and biotech industries.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.